home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
  HUM-MOLGEN -> Events -> Meetings and Conferences  
 

Expectations for Products Used in Early Phase

 
  March 28, 2018  
     
 
Netzealous LLC DBA - Compliance4All, Online
2018-05-16


Overview:
This presentation will review the GMP guidance document and discuss how it may be integrated with the recommendations of the guidance documents on CMC requirements.

Areas Covered in the Session:
Discussion of the elements found in the guidance document for Phase 1 material
What to do at really early stages
What about special IND studies?
What about preclinistudies?

Who Will Benefit:
Regulatory Affairs Personnel who Coordinate Activities for the CMC Sections of Submissions
QA/QC Personnel who Need to Plan Work on Early Stage Material
R & D Personnel who Will Contribute data to CMC Sections
Project Managers for Product Development Studies

Event Fee: One Dial-in One Attendee Price: US$150.00

Contact Detail:
Compliance4All DBA NetZealous,
Phone: +1-800-447-9407
Email: support@compliance4All.com
 
 
Organized by: Event Manager
Invited Speakers: Speaker Profile
Steven S. Kuwahara , Ph.D. is the founder and Principal of GXP BioTechnology LLC, a consulting firm that works in the areas covered by the GLP and GMP of drugs, biologics, and nutraceuticals. Steve has over 30 years of experience in supervising quality control laboratories, including an animal testing facility, and in performing GLP and GMP audits of internal and external testing laboratories . Steve has participated in the development of drugs and biologicals through all phases of clinical research and final product production.
 
Deadline for Abstracts: 2018-05-15
 
Registration: http://www.compliance4all.com/control/w_product/~product_id=501877LIVE?channel=molgen_May_2018_SEO
E-mail: support@compliance4All.com
 
   
 
home   genetic news   bioinformatics   biotechnology   literature   journals   ethics   positions   events   sitemap
 
 
 

Generated by meetings and positions 5.0 by Kai Garlipp
WWW: Kai Garlipp, Frank S. Zollmann.
7.0 © 1995- HUM-MOLGEN. All rights reserved. Liability, Copyright and Imprint.